This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Vifor (International) Ag. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Naja Nyffenegger: Innovator in Ferroportin Inhibitors
Introduction
Naja Nyffenegger is a prominent inventor based in St. Gallen, Switzerland. She has made significant contributions to the field of medicine, particularly in the treatment of transfusion-dependent beta-thalassemia (TDT). Her innovative work focuses on the development of ferroportin inhibitors, which play a crucial role in managing this condition.
Latest Patents
Naja holds a patent for "Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia." This invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent β-thalassemia. Her patent represents a significant advancement in therapeutic options for patients suffering from this genetic disorder. She has 1 patent to her name.
Career Highlights
Naja Nyffenegger is currently associated with Vifor International AG, where she continues to work on innovative solutions in the field of hematology. Her dedication to research and development has positioned her as a key figure in the medical community.
Collaborations
Throughout her career, Naja has collaborated with notable professionals, including Franz Dürrenberger and Vania Manolova. These partnerships have enhanced her research efforts and contributed to the advancement of her projects.
Conclusion
Naja Nyffenegger's work in developing ferroportin inhibitors showcases her commitment to improving treatment options for transfusion-dependent beta-thalassemia. Her contributions to the field of medicine are invaluable and highlight the importance of innovation in healthcare.